1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A

1.82
EUR
+0.00
(+0.25%)
0.16EPS
17.58P/E
9.53BMarket Cap
Oct 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.69
3.14
3.29
3.78
4.51
5.9
6.7
7.09
9.14
10.09
9.25
9.24
9.4
11.86
Basic EPS, GAAP
0.43
0.55
0.64
0.72
0.76
0.64
0.78
0.86
1.11
0.86
0.53
0.62
0.76
0.97
Free Cash Flow per Basic Share
-0.01
0.02
0.1
0.05
0.1
-0.05
-0.17
-0.43
-0.24
-0.38
-0.43
0.02
0.17
- -
Dividend per Share
0.22
0.25
0.29
0.31
0.35
0.42
0.44
0.43
0.45
0.55
0.55
0.46
0.44
0.3
Book Value per Share
4.1
4.32
4.71
5.51
6.08
6.54
7.45
8.65
9.16
10
10.24
10.6
10.93
11.03
Tangible Book Value per Share
2.6
2.72
3.01
3.74
2.06
2.32
2.78
3.93
3.82
4.11
3.91
3.82
4.04
3.75
Basic Weighted Avg Shares
3,721
3,833
3,838
3,871
4,107
4,224
4,265
4,275
4,267
4,355
4,475
4,446
4,430
3,528
Sales/Revenue/Turnover
9,996
12,026
12,609
14,629
18,534
24,918
28,585
30,307
39,011
43,952
41,400
41,067
41,662
41,856
Operating Margin (%)
11.14
9.92
11.69
11.91
12.43
9.5
9.15
9.34
6.95
8.27
3.78
7.8
7.55
7.76
Depreciation Expense
416
558
649
733
939
1,320
1,472
1,666
1,834
2,336
2,965
3,002
3,513
- -
Net Income, GAAP
1,583
2,113
2,460
2,806
3,124
2,708
3,322
3,663
4,729
3,731
2,386
2,770
3,371
3,420
Effective Tax Rate (%)
15.48
12.81
14.86
9.81
11.73
15.64
17.28
15.77
17.65
13.7
11.32
15.75
16.9
18.3
Profit Margin (%)
15.83
17.57
19.51
19.18
16.86
10.87
11.62
12.09
12.12
8.49
5.76
6.74
8.09
8.17
Working Capital
1,708
-873
-2,614
656
-1,544
78
2,970
212
1,118
1,981
35
-2,962
-2,604
-2,616
LT Debt
4,200
3,857
3,572
5,571
9,815
12,996
12,987
9,103
9,697
12,845
15,555
12,985
14,913
15,504
Total Equity
17,665
19,103
20,670
25,250
29,741
33,593
39,204
45,984
48,380
54,109
56,616
59,934
61,840
63,669
Return on Invested Capital (%)
8.53
8.23
9.49
8.9
8.25
5.52
6.23
6.03
7.24
5.08
3.31
3.8
4.42
4.46
Return on Capital (%)
6.88
8.84
8.38
8.32
7.34
5.93
6.4
6.3
7.23
5.54
3.47
3.44
3.62
3.49
Return on Common Equity (%)
10.96
13.2
14.12
13.9
13.15
10.16
11.1
10.63
12.41
8.91
5.29
5.96
7.02
7.09

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
ST Debt
22,645
23,179
24,028
LT Borrowings
11,595
11,862
12,577
LT Finance Leases
2,754
3,051
2,927
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,457
4,457
4,457
Market Capitalization
66,530
75,914
75,983

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
Total Current Assets
34,342
33,821
33,965
Cash, Cash Equivalents & STI
15,639
15,358
15,293
Accounts Receivable, Net
8,481
9,365
9,468
Inventories
6,744
6,252
6,032
Total Current Liabilities
36,023
36,424
36,581
Payables & Accruals
- -
- -
- -
ST Debt
22,645
23,179
24,028
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.76%
6.14%
3.18%
Free Cash Flow
126.56%
194.76%
1,045.04%
Net Income, GAAP
5.47%
1.95%
21.69%
Sales/Revenue/Turnover
13.41%
7.24%
1.45%
Total Cash Common Dividend
6.51%
2.02%
-5.57%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,157
10,306
10,449
10,155
41,067
2025
9,420
10,094
- -
12,268
41,662
2026
10,073
- -
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.23
0.18
0.28
0.62
2025
0.17
0.35
- -
0.32
0.76
2026
0.2
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.12
0.23
0.13
0.46
2025
0.07
0.11
- -
0.09
0.44
2026
0.06
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yi Liu
Full Time Employees
40,603
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building A Shanghai SH China 200233
IPO Date
Aug 7, 1998
Website
fosunpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS), founded in 1994 and headquartered in Shanghai, China, is an innovation-driven pharmaceutical and healthcare company that engages in the research, development, manufacturing, and commercialization of pharmaceutical products; medical devices and diagnostics; healthcare services; and pharmaceutical distribution and retail, primarily in China with operations extending to the United States, Europe, the Middle East, Africa, India, Southeast Asia, and other international markets. Its core pharmaceutical manufacturing portfolio spans oncology and immunomodulation products such as Han Qu You (Trastuzumab for Injection), Han Li Kang (Rituximab Injection), Han Si Zhuang (Serplulimab Injection), and Doptelet (Avatrombopag Maleate Tablets); metabolism and digestive system therapies including You Li Tong (Febuxostat Tablets), human and animal insulin preparations, and Wan Su Jing (Empagliflozin Tablets); anti-infection treatments like Comirnaty (mRNA COVID-19 Vaccine), Jie Bei An (Azvudine Tablets), and antimalarial drugs such as artesunate; central nervous system medications including Qi Wei (Quetiapine Fumarate Tablets) and Qi Cheng (Escitalopram Oxalate Tablets); cardiovascular products such as heparin preparations, Bang Tan (Telmisartan Tablets), and Ya Ni An (Amlodipine Besylate Tablets); and active pharmaceutical ingredients like amino acid series and tranexamic acid. The company targets diverse customer segments including hospitals, clinics, wholesalers, and patients, with a robust R&D pipeline exceeding 80 projects focused on oncology, immune-inflammatory disorders, antibody/ADC platforms, cell therapies, small molecules, radiopharmaceuticals, RNA therapeutics, gene editing, and AI-powered drug discovery; it reported FY2024 revenue of RMB41.07 billion, R&D expenditure of RMB5.554 billion, and over 40,000 global employees. Recent developments include subsidiary Henlius forging partnerships with over 20 global biopharma firms such as Accord, Abbott, Eurofarma, Organon, and Dr. Reddy’s for biologics commercialization in Europe, the U.S., and emerging markets; establishing a joint venture with SVAX in Saudi Arabia via Fosunhenlius Middle East United Company to expand in the MENAT region; Fosun Pharma acquiring full 100% ownership of cell therapy platform Fosun Kite (formerly Fosun Kairos) from Kite Pharma for $27 million plus $10 million investment to advance CAR-T therapies like Yi Kai Da (Axi-Cel) and FKC889 in Greater China; and announcing 2025 interim and Q3 financial results reflecting steady global expansion and improved operating cash flows.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) Q2 2026 Earnings Call Transcript

  • prnewswire.com

    Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion

  • defenseworld.net

    Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (OTCMKTS:SFOSF) Short Interest Up 21.2% in January

  • prnewswire.com

    ElpasBio and Fosun Kairos Announce Commercialization Collaboration for AlloJoin® Stem Cell Therapy

  • reuters.com

    Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse

  • forbes.com

    Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech

  • seekingalpha.com

    Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal

  • seekingalpha.com

    Pandemic Accelerates China's Drive Into mRNA Treatments

  • seekingalpha.com

    Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse

  • seekingalpha.com

    Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal